A Clinical Study of Different Concentrations of Timoiol Maleate Eye Drops for the Treatment of Superficial Infantile Hemangiomas

Expand
  • Department of Pediatric Surgery, Taizhou Hospital of Zhejiang Province Affiliated To Wenzhou Medical University, Linhai 317000, China

Received date: 2020-04-20

  Revised date: 2020-05-15

  Online published: 2020-06-26

Abstract

Objective To explore the efficacy and safety of timolol maleate eye drops with different concentrations for the treatment of superficial infantile hemangiomas.

Methods From January 2018 to January 2019, patients aged within 6 months with superficial infantile hemangiomas were enrolled, and were randomly divided into 2 groups according to different concentration of timolol maleate eye drops: 0.25% timolol group and 0.5% timolol group. Tiamolol maleate eye drops were applied externally by wet compressing for 20 minutes, three times a day for 6 months. The therapeutic effect was categorized into four grades, the therapeutic effect and safety of the two groups were compared.

Results A total of 87 patients with superficial infantile hemangiomas were included in the study and were divided into 0.25% timolol group (n=41) and 0.5% timolol group (n=46). Six months after treatment, the effective rate and cure rate of 0.25% timolol group were 63.4% and 14.6%, the effective rate and cure rate of 0.5% timolol group were 82.6% and 19.6%. The effective rate of 0.5% timolol group was significantly higher than that of 0.25% timolol group (P<0.05). There was no significant difference of cure rate between the two groups (P>0.05). No severe systemic or local adverse reactions were observed during treatment.

Conclusion Topical application of timolol maleate eye drops in the treatment of superficial infantile hemangiomas during proliferative phase is simple, effective and safe. Drug concentration may be one of the factors influencing clinical efficacy.

Cite this article

Shengmiao LI, Chunfen LUO, Jiachuan XU, Linjun YU . A Clinical Study of Different Concentrations of Timoiol Maleate Eye Drops for the Treatment of Superficial Infantile Hemangiomas[J]. Journal of Tissue Engineering and Reconstructive Surgery, 2020 , 16(3) : 179 -181 . DOI: 10.3969/j.issn.1673-0364.2020.03.001

References

[1] 中华医学会整形外科分会血管瘤和脉管畸形学组. 血管瘤和脉管畸形的诊断及治疗指南(2019 版)[J]. 组织工程与重建外科杂志, 2019,15(5):277-317.
[2] 陶超, 徐仙赟, 刘海金 , 等. 不同β-受体阻滞剂治疗婴幼儿型血管瘤临床应用的研究进展[J]. 中华小儿外科杂志, 2019,40(3):272-276.
[3] Léauté-Labrèze C , Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy[J]. N Engl J Med, 2008,358(24):2649-2651.
[4] Guo S, Ni N . Topical treatment for capillary hemangioma of the eyelid using β-blocker solution[J]. Arch Ophthalmol, 2010,128(2):255-256.
[5] 於林军, 许嘉川, 苏宝利 , 等. 马来酸噻吗洛尔滴眼液治疗婴幼儿表浅血管瘤的临床研究[J]. 中华整形外科杂志, 2015,31(6):440-445.
[6] Dalla Costa R, Prindaville B, Wiss K . Doing the math: A simple approach to topical timolol dosing for infantile hemangiomas[J]. Pediatr Dermatol, 2018,35(2):276-277.
[7] Waner M, Suen JY . A classification of congenital vascular lesions[M] //Waner M, Suen JY. Hemangiomas and vascular malformations of the head and neck. New York: Wiley-Liss, 1999: 1-12.
[8] Achauer BM, Chang CJ, Vander Kam VM . Management of hemangioma of infancy: review of 245 patients[J]. Plast Reconstr Surg, 1997,99(5):1301-1308.
[9] 仇雅璟, 陈敏燕, 常雷 , 等. 马来酸噻吗洛尔外用凝胶治疗浅表型婴幼儿血管瘤的随机双盲前瞻性临床研究[J]. 组织工程与重建外科杂志, 2014,10(4):203-206.
[10] Chakkittakandiyil A, Phillips R, Frieden IJ , et al. Timolol maleate 0.5% or 0.1% gel-forming solution for infantile hemangiomas: a retrospective, multicenter, cohort study[J]. Pediatr Dermatol, 29(1):28-31.
[11] 陈彬, 仇雅璟, 林晓曦 . 婴幼儿血管瘤外用药物治疗研究进展[J]. 中华整形外科杂志, 2019,35(5):502-506.
Outlines

/